Charles River Laboratories (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 200,321 | 241,869 | 241,214 | 212,539 | 222,969 |
| Receivables | 747,605 | 697,843 | 642,881 | 660,452 | 644,027 |
| Inventories | 256,765 | 221,175 | 199,146 | 181,694 | 194,341 |
| Other current assets | 107,456 | 81,703 | 97,311 | 246,828 | 121,966 |
| TOTAL | $1,393,086 | $1,333,086 | $1,274,095 | $1,379,040 | $1,267,913 |
| Non-Current Assets | |||||
| PPE Net | 1,383,422 | 1,321,618 | 1,291,068 | 1,175,911 | 1,189,120 |
| Investments And Advances | 0 | 0 | 201,352 | 0 | 0 |
| Intangibles | 2,927,424 | 2,766,701 | 3,773,073 | 2,823,596 | 2,632,518 |
| Other Non-Current Assets | 1,825,429 | 1,653,643 | 484,704 | 1,679,889 | 1,630,801 |
| TOTAL | $6,136,275 | $5,741,962 | $5,750,197 | $5,679,396 | $5,452,439 |
| Total Assets | $7,529,361 | $7,075,049 | $7,024,292 | $7,058,437 | $6,720,352 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 2,364 | 2,642 | N/A | 2,275 | 3,021 |
| Accounts payable and accrued liabilities | 211,381 | 225,977 | 198,130 | 127,913 | 110,926 |
| Accrued Expenses | 402,196 | 392,427 | 474,916 | 467,835 | 452,035 |
| Other current liabilities | 190,110 | 144,533 | 140,436 | 163,997 | 132,299 |
| TOTAL | $1,048,135 | $993,839 | $1,033,185 | $983,751 | $929,610 |
| Non-Current Liabilities | |||||
| Long Term Debt | 2,997,221 | 2,676,165 | 2,663,564 | 2,892,676 | 2,727,240 |
| Deferred Revenues | 242,084 | 228,260 | 219,703 | 221,731 | 231,329 |
| Other Non-Current Liabilities | 599,684 | 556,986 | 546,592 | 489,093 | 476,192 |
| TOTAL | $3,828,299 | $3,466,304 | $3,452,125 | $3,642,621 | $3,467,462 |
| Total Liabilities | $4,876,434 | $4,460,143 | $4,485,310 | $4,626,372 | $4,397,072 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 50,863 | 50,805 | 50,486 | 50,464 | 50,397 |
| Common Shares | 510 | 509 | 505 | 506 | 505 |
| Retained earnings | 1,183,094 | 1,073,773 | 980,751 | 878,818 | 775,392 |
| Other shareholders' equity | -253,802 | -170,205 | -160,578 | -127,720 | -103,478 |
| TOTAL | $2,652,927 | $2,614,906 | $2,538,982 | $2,432,065 | $2,323,280 |
| Total Liabilities And Equity | $7,529,361 | $7,075,049 | $7,024,292 | $7,058,437 | $6,720,352 |